Prostate Cancer Clinical Research Trials

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Homewood :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Mobile : Providence Cancer Center at Providence Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Muscle Shoals : Investigational Site Number 840002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Muscle Shoals : Investigational Site Number 840004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Anchorage : Providence Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Anchorage : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Fairbanks : Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Glendale : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Phoenix : Precision Trials, LLC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Phoenix : Caris Science, Inc.

EMBRACE1: Prostate Biorepository

Phoenix : Foundation for Cancer Research and Education

SpaceOAR System Pivotal Study

Phoenix : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Phoenix, Mesa, Scottsdale, Glendale : Arizona Oncology Services Foundation

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Scottsdale : 21st Century Oncology

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Scottsdale :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Scottsdale : TGen Clinical Research Services

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Scottsdale :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Tucson :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Tucson :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Tucson : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Tuscon : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Hot Springs : Investigational Site Number 840004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hot Springs : Investigational Site Number 840002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Jonesboro : NEA Medical Clinic - East Matthews

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Little Rock : Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duarte : City of Hope

A Prospective Randomized Trial of Pelvic Drain Placement Versus no Pelvic Drain Placement After Robotic Assisted Laparoscopic Prostatectomy (RALP) in Patients with Prostate Cancer

Duarte : City of Hope

A Randomized, Phase II Study, Assessing Axitinib as Pre-Surgical Therapy in Patients with High Risk Prostate Cancer

Duarte : City of Hope

Assessment of Changes in Inflammatory Cytokines and Downstream Mediators of Prostate Carcinogenesis in Patients Receiving Radiation Therapy for Localized Prostate Cancer

Duarte : City of Hope

Assessment of the Relationship Between Changes in PSA and Peripheral pStat3 Levels, MDSC Quantity and VKOR Mutation in Castrate Resistant Prostate Cancer

Duarte : City of Hope

Long Term Follow Up after Prostate Cancer

Duarte : City of Hope

Pre-Surgical EPS Biomarkers as Predictors of Recurrence

Duarte : City of Hope

Prostate Cancer Database

Duarte : City of Hope

SWOG S1014: Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II

Anaheim : Investigational Site Number 840008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Anaheim : Investigational Site Number 840009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Anaheim :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Atherton : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Bakersfield : Investigational Site Number 840014

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Baldwin Park :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Beverly Hills : Westside Prostate Cancer Center, University of Southern California

Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

Burbank :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Burbank :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Campbell : Urological Surgeons of Northern California

SpaceOAR System Pivotal Study

Castro Valley : East Bay Radiation Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Castro Valley : Valley Medical Oncology Consultants - Castro Valley

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Concord : Cancer Care Center at John Muir Health - Concord Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duarte : City of Hope Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Encinitas :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Escondido : San Diego Radiosurgery at Palomar Medical Center Updated

Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer

Fairfield : North Bay Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fontana :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Fremont : Valley Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grass Valley : Sierra Nevada Cancer Center at Sierra Nevada Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hayward :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Highland : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

La Jolla : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

La Mesa : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Laguna Hills : South Orange County Medical Research Center

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Long Beach : Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Long Beach : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Los Angeles :

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Los Angeles : University of California, Los Angeles Institute of Urologic Oncology

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Los Angeles : University of Southern California

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Los Angeles :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Los Angeles : Tower Urology / Tower Research Institute

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Los Angeles : David Geffen School of Medicine at UCLA

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Los Angeles : USC/Norris Comprehensive Cancer Center and Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Los Angeles :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Los Angeles : USC/Norris Comprehensive Cancer Center

Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

Los Angeles :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Los Angeles : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Marina Del Rey : Prostate Oncology Specialists

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Marina del Rey :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Marina del Rey :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Martinez : Contra Costa Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marysville : Tibotec Therapeutics - Division of Ortho Biotech Products, LP

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Merced : Mercy Cancer Center at Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Modesto : Investigational Site Number 840030

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Montebello : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Mountain View : El Camino Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Murrieta : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Oakland : Alta Bates Summit Medical Center - Summit Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Highland General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Bay Area Breast Surgeons, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : CCOP - Bay Area Tumor Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Epic Care - Oakland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Larry G Strieff MD Medical Corporation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Tom K Lee, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Orange : St. Joseph Hospital Regional Cancer Center - Orange

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Orange : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Orange : Chao Comprehensive Cancer Center

Trail of Taxotere Plus Sunitinib on Newly Diagnosed, Hormone Refractory, Metastatic Prostate Cancer

Palo Alto :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Pleasanton : Valley Medical Oncology Consultants - Pleasanton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rancho Mirage : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Roseville :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Sacramento : University of California Davis Cancer Center

Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer

Sacramento : University of California Davis Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sacramento :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Sacramento : Radiological Associates of Sacramento

SpaceOAR System Pivotal Study

Sacramento : University of California at Davis

Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer

San Bernardino : San Bernardino Urological Associates

A 2 Part Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

San Bernardino : Investigational Site Number 840001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

San Bernardino : Investigational Site Number 840003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

San Bernardino :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Bernardino : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

San Diego :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

San Diego : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

San Diego : Sharp Health Care

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

San Diego : Genesis Research

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

San Diego :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

San Diego :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Diego :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

San Diego : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

San Diego : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

San Diego : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

San Francisco :

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

San Francisco : University of California, San Francisco

Abiraterone Post Ketoconazole for Prostate Cancer

San Francisco : Investigational Site Number 840001

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

San Francisco : Investigational Site Number 840010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

San Francisco : Investigational Site Number 840012

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

San Francisco : California Pacific Medical Center Research Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

San Francisco :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

San Francisco : University of California, San Francisco

Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC

San Francisco :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Francisco : University of California San Francisco (UCSF) Medical Center

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

San Jose :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Luis Obispo : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

San Marcos :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Pablo : Doctors Medical Center - San Pablo Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Santa Clara :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Santa Monica : University of California Los Angeles (UCLA)

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

South San Francisco :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Stanford :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Stockton : Investigational Site Number 840022

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Torrance :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Torrance : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Truckee : Tahoe Forest Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Vallejo :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Vallejo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Walnut Creek : John Muir/Mt. Diablo Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Walnut Creek :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Denver : The Urology Center of Colorado

A Phase 4, placebo controlled study to evaluate the efficacy and safety of VESIcare to improve urinary incontinence in men after robotic assisted radical prostatectomy

Denver : The Urology Center of Colorado

A Phase 4, placebo controlled study to evaluate the efficacy and safety of VESIcare to improve urinary incontinence in men after robotic assisted radical prostatectomy

Denver : The Urology Center of Colorado

A Phase II study of Abiraterone Acetate plus Prednisone in subjects with advanced prostate cancer without radiographic evidence of metastatic disease

Denver : The Urology Center of Colorado

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Denver : The Urology Center of Colorado

International, open label, randomized study assessing the safety and efficacy of a monthly dosing regimen of Ozarelix vs. Goserlin Depot (Zoladex) in men with prostate cancer.

Denver : The Urology Center of Colorado

Open, non-randomized, uncontrolled, multiple dose escalation study of the safety and effectiveness of an investigational drug (ODM-201) for men with advanced prostate cancer.

Denver : The Urology Center of Colorado

Phase 2 multicenter prospective open label, 2- dose level clinical trial studying the safety and efficacy of an injection of NX-1207 for the treatment of low risk, localized (T1c) prostate cancer.

Denver : The Urology Center of Colorado

Phase II efficacy and safety study of MDV3100 vs. bicalutamide in castrate men with metastatic prostate cancer

Denver : The Urology Center of Colorado

Phase II, double blind, efficacy and safety study of Enzalutamide vs. Bicalutamide in men with prostate cancer who have failed primary androgen deprivation therapy.

Denver : The Urology Center of Colorado

Study to Evaluate New or Worsening Lens Opacifications in Subjects with Nonmetastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy

Aurora :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Aurora : Aurora Presbyterian Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Aurora :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Aurora : University of Colorado Cancer Center

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Aurora : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Aurora : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Boulder : Rocky Mountain Cancer Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Boulder : Boulder Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Colorado Springs : Memorial Hospital Cancer Center - Colorado Springs

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Colorado Springs : Penrose Cancer Center at Penrose Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Denver : Investigational Site Number 840019

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Denver :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Denver : The Urology Center of Colorado

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Denver : The Urology Center of Colorado

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Denver : Genitourinary Surgical Consultants

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Denver : Porter Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : St. Joseph Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : CCOP - Colorado Cancer Research Program

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Presbyterian - St. Luke's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Rose Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : St. Anthony Central Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Denver : The Urology Center of Colorado

SpaceOAR System Pivotal Study

Denver : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Englewood : Swedish Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Englewood : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Fort Collins : Front Range Cancer Specialists

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Collins : Poudre Valley Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Golden : Foothills Urology

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Grand Junction : St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greeley : North Colorado Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Littleton : Littleton Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Littleton :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Lone Tree : Sky Ridge Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Longmont : Hope Cancer Care Center at Longmont United Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Loveland : McKee Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Parker : Advanced Urology

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Parker : Parker Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pueblo : St. Mary - Corwin Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Thornton : North Suburban Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wheat Ridge : Exempla Lutheran Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wheat Ridge : The Urology Center of Colorado

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Wheat Ridge : The Urology Center of Colorado

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Hartford : Investigational Site Number 840031

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Hartford : Hartford Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Hartford : Saint Francis Hospital and Medical Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Hartford : Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Middlebury : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Middlebury : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

New Britain : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

New Britain : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

New Haven :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Norwalk :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Norwich : Eastern CT Hematology and Oncology Associates

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Norwich : Eastern CT Hematology and Oncology Associates

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Southington : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Stamford : Investigational Site Number 840021

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Stamford : Investigational Site Number 840029

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lewes : Tunnell Cancer Center at Beebe Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newark : Helen F. Graham Cancer Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Newark : CCOP - Christiana Care Health Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Washington :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Washington :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Aventura : South Florida Medical Research

Metastatic, Androgen-Independent study for patients with Prostate Cancer

Aventura : South Florida Medical Research, Inc.

Phase IV, Hormone Refractory Prostate Cancer Study

Fort Lauderdale : Holy Cross Hospital

AT13387-04

Tallahassee : Southeastern Research Group, Inc.

Prostate Cancer - A Phase III, Open-Label Trial of Degarelix Intermittent Therapy vs. Continuous Androgen Deprivation Therapy with Leuprolide or Degarelix in patients with carcinoma of the prostate with biochemical failure after localized therapy

Tampa : H. Lee Moffitt Cancer Center & Research Institute

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

Aventura :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Aventura : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Aventura : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Boca Raton : Investigational Site Number 840013

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Boca Raton :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Bradenton : Lakewood Ranch Oncology Center/21st Century Oncology

SpaceOAR System Pivotal Study

Daytona Beach : Atlantic Urological Associates

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Daytona Beach :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Fort Lauderdale : Holy Cross Hospital

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Fort Lauderdale : Broward General Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Meyers : 21st Century Oncology

SpaceOAR System Pivotal Study

Fort Myers : Florida Cancer Specialists

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Fort Myers : 21st Century Oncology

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Inverness : Florida Cancer Specialists

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Jacksonville : Investigational Site Number 840023

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Jacksonville : Investigational Site Number 840035

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Jacksonville :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Lakeland : Lakeland Regional Cancer Center

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Lakeland : Investigational Site Number 840013

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Naples :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Naples : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Ocala : Urology Health Team

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Orange City : Atlantic Urological Associates

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Orange City :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Orange City :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Orlando : MD Anderson-Orlando-Orlando Health

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Orlando : Winter Park Urology Associates, PA

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Orlando : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Pensacola : Sacred Heart Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pensacola : Sacred Heart Cancer Center at Sacred Heart Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Port St. Lucie :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Port St. Lucie : Investigational Site Number 840003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Port St. Lucie : Investigational Site Number 840001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Sarasota : Florida Urology Specialists

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Sarasota : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

St Petersburg : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

Tampa : H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tampa : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Titusville : Space Coast Medical Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Trinity : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Wellington : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

West Palm Beach : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Savannah : Memorial University Medical Center

SWOG S1014: Phase II Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy

Athens : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Atlanta : Piedmont Healthcare Research Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Atlanta :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Atlanta : CCOP - Atlanta Regional

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Piedmont Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Northside Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Saint Joseph's Hospital of Atlanta

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Emory University

SpaceOAR System Pivotal Study

Atlanta : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Austell : WellStar Cobb Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : John B. Amos Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Decatur : Charles B. Eberhart Cancer Center at DeKalb Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fayetteville : Piedmont Fayette Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fayetteville : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Gainesville : Northeast Georgia Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lawrenceville : Gwinnett Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marietta : Georgia Cancer Specialists, P.C.

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Marietta : Kennestone Cancer Center at Wellstar Kennestone Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marietta : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Riverdale : Southern Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rome : Harbin Clinic Cancer Center - Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Savannah : Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Valdosta : Pearlman Comprehensive Cancer Center at South Georgia Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Aiea : Kapiolani Medical Center at Pali Momi

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Kapiolani Medical Center for Women and Children

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : OnCare Hawaii, Incorporated - Lusitana

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Straub Clinic and Hospital, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Cancer Research Center of Hawaii

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Hawaii Medical Center - East

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : OnCare Hawaii, Incorporated - Kuakini

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Queen's Cancer Institute at Queen's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Tripler Army Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lihue : Kauai Medical Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wailuku : Pacific Cancer Institute - Maui

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wailuku : Maui Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Boise : Mountain States Tumor Institute at St. Luke's Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Boise : Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Coeur d'Alene : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Coeur d'Alene : North Idaho Urology

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Fruitland : Saint Luke's Mountain States Tumor Institute - Fruitland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lewiston : St. Joseph Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Meridian : Idaho Urologic Institute

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Meridian : Mountain States Tumor Institute - Meridian

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Nampa : Saint Luke's Mountain States Tumor Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Twin Falls : Mountain States Tumor Institute at St. Luke's

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elgin : Sherman Health

ECOG E2809 Phase II Randomized Study of Bicalutamide With Versus Without Akt Inhibitor MK2206 in Patients With Prostate Cancer and Rising PSA at High-Risk of Progression After Primary Therapy

Elgin : Sherman Health

ECOG E3805 Phase III Randomized Study of Chemohormonal Therapy Versus Androgen-Ablation Therapy in Patients With Extensive Metastatic Prostate Cancer

Elgin : Sherman Health

SWOG S0925 Phase II Randomized Study of Combined Androgen Deprivation Comprising Bicalutamide and Goserelin or Leuprolide Acetate With Versus Without Cixutumumab in Patients With Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer

Elgin : Sherman Health

SWOG S1014 Phase II Study of Abiraterone Acetate in Patients With Metastatic Prostate Cancer and a Sub-Optimal Prostate-Specific Antigen Following Initial Androgen-Deprivation Therapy

Elk Grove Village : Alexian Brothers Hospital Network

A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.

Aurora : Rush-Copley Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Carbondale : Memorial Hospital of Carbondale

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago :

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Chicago : University of Chicago

Abiraterone Post Ketoconazole for Prostate Cancer

Chicago : The University of Chicago

Pazopanib, Docetaxel, Prednisone Prostate

Chicago : John H. Stroger, Jr. Hospital of Cook County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago : Louis A. Weiss Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago : Northwestern University

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Chicago :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Decatur : Investigational Site Number 840015

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Decatur : Decatur Memorial Hospital Cancer Care Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elgin : Sherman Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Evanston :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Evanston : Evanston Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Evanston : North Shore University

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Galesburg :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Galesburg : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Geneva : Delnor Hospital - Geneva

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Glenview :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Hines : Veterans Affairs Medical Center - Hines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maywood : Cardinal Bernardin Cancer Center at Loyola University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Melrose Park : Uropartners/RMD Clinical Research

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Melrose Park :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Moline : Trinity Cancer Center at Trinity Medical Center - 7th Street Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Moline :

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Vernon : Good Samaritan Regional Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Niles : Oncology Specialists, SC

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Niles : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Park Ridge : Oncology Specialists, S.C.

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

River Forest : West Suburban Center for Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Springfield : Southern Illinois University School of Medicine

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Springfield : Regional Cancer Center at Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Urbana : CCOP - Carle Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Warrenville : Central Dupage Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Beech Grove : St. Francis Hospital and Health Centers - Beech Grove Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Elkhart Clinic, LLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Elkhart General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Michiana Hematology-Oncology, PC - Elkhart

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Wayne :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Greenwood : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Greenwood : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Indianapolis : Indiana University School of Medicine

Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling

Indianapolis : Indiana University Simon Cancer Center

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Indianapolis :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Jeffersonville : First Urology

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Jeffersonville :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Jeffersonville :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Jeffersonville : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Jeffersonville : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Kokomo : Howard Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

La Porte : Center for Cancer Therapy at LaPorte Hospital and Health Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Michigan City : Saint Anthony Memorial Health Centers

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mishawaka : Michiana Hematology-Oncology, PC - South Bend

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mishawaka : Saint Joseph Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Plymouth : Michiana Hematology Oncology PC - Plymouth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Richmond : Reid Hospital & Health Care Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

South Bend : CCOP - Northern Indiana CR Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

South Bend : Memorial Hospital of South Bend

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Westville : Michiana Hematology Oncology PC - La Porte

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ames : McFarland Clinic, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bettendorf :

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar Rapids : Cedar Rapids Oncology Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar Rapids : Mercy Regional Cancer Center at Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Clive : Medical Oncology and Hematology Associates - West Des Moines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Davenport : Genesis Regional Cancer Center at Genesis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : John Stoddard Cancer Center at Iowa Lutheran Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Medical Oncology and Hematology Associates at Mercy Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : CCOP - Iowa Oncology Research Association

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : John Stoddard Cancer Center at Iowa Methodist Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Medical Oncology and Hematology Associates at John Stoddard Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Mercy Cancer Center at Mercy Medical Center - Des Moines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mason City : Mercy Cancer Center at Mercy Medical Center - North Iowa

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : Mercy Medical Center - Sioux City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : Siouxland Hematology-Oncology Associates, LLP

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : St. Luke's Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

West Des Moines : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Chanute : Cancer Center of Kansas, PA - Chanute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dodge City : Cancer Center of Kansas, PA - Dodge City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

El Dorado : Cancer Center of Kansas, PA - El Dorado

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Scott : Cancer Center of Kansas - Fort Scott

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Independence : Cancer Center of Kansas-Independence

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kingman : Cancer Center of Kansas, PA - Kingman

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lawrence : Lawrence Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Liberal : Cancer Center of Kansas, PA - Liberal

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

McPherson : Cancer Center of Kansas, PA - McPherson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newton : Cancer Center of Kansas, PA - Newton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Overland Park : Kansas City Urology Care, PA

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Overland Park : Menorah Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Overland Park : Saint Luke's Hospital - South

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Parsons : Cancer Center of Kansas, PA - Parsons

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Prairie Village : CCOP - Kansas City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pratt : Cancer Center of Kansas, PA - Pratt

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salina : Cancer Center of Kansas, PA - Salina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salina : Tammy Walker Cancer Center at Salina Regional Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Topeka : Cotton-O'Neil Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wellington : Cancer Center of Kansas, PA - Wellington

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Westwood :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Wichita : Investigational Site Number 840018

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Wichita : Cancer Center of Kansas

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Wichita : Cancer Center of Kansas

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Wichita : Cancer Center of Kansas, PA - Wichita

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Associates in Womens Health, PA - North Review

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Cancer Center of Kansas, PA - Medical Arts Tower

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : CCOP - Wichita

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Via Christi Cancer Center at Via Christi Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Winfield : Cancer Center of Kansas, PA - Winfield

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hazard : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Louisville : Baptist Hospital East

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Louisville :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Paducah : Investigational Site Number 840010

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Baton Rouge : Ochsner Health Center - Bluebonnet

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Covington : Ochsner Health Center - Covington

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Matairie :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Monroe : Louisiana State University Health Sciences Center - Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Orleans :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

New Orleans : Investigational Site Number 840007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

New Orleans : Investigational Site Number 840008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

New Orleans :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

New Orleans : Tulane University

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

New Orleans : CCOP - Ochsner

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Orleans : Ochsner Cancer Institute at Ochsner Clinic Foundation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Orleans :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Shreveport : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Shreveport : Feist-Weiller Cancer Center at Louisiana State University Health Sciences

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Shreveport : Highland Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Shreveport :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Shreveport : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Annapolis : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Annapolis : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Baltimore : University of Maryland, Greenebaum Cancer Center

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Baltimore : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Baltimore : Johns Hopkins University

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Baltimore : Investigational Site Number 840014

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Baltimore : The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Baltimore : Johns Hopkins Medical Institutions

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Baltimore : Johns Hopkins University Department of Radiation Oncology and Molecular Radiation Sciences

SpaceOAR System Pivotal Study

Baltimore :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Baltimore : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Bethesda : Center for Cancer & Blood Disorders

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike

GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

Bethesda : Walter Reed National Military Medical Center

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Bethesda : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Elkton MD : Union Hospital of Cecil County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenbelt : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Greenbelt : Mid Atlantic Clinical Research

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Owings Mills : Chesapeake Urology Associates, Chesapeake Urology Research Associates (The Prostate Center)

SpaceOAR System Pivotal Study

Rockville :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Rockville : Investigational Site Number 840005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Rockville : Investigational Site Number 840006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Rockville :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Towson :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Towson :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Towson : GTX Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Boston : Dana-Farber Cancer Institute

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Boston : Beth-Israel Deaconess Medical Center

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Boston : Investigational Site Number 840138

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Boston : Investigational Site Number 840238

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Boston : Boston University Medical Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Boston : Dana-Farber Cancer Institute and (Sanofi-Aventis Consortium)

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Boston :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Boston : Beth Israel Deaconess Medical Center

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

Boston : Dana-Farber Cancer Institute

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

Boston : Massachusetts General Hospital Cancer Center

Safety Study of MGA271 in Refractory Cancer

Boston : Dana-Farber Cancer Institute

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

Boston : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Boston :

Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Brookline : Investigational Site Number 840038

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Methuen : Caritas Holy Family Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Methuen : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Rockland : Contact US Medical Information in Rockland, MA for US Recruiting Sites

L-BLP25 (Stimuvax) in Prostate Cancer

Worcester : University of Massachusetts Medical School

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Ann Arbor : University of Michigan

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

Adrian : Hickman Cancer Center at Bixby Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : Saint Joseph Mercy Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : CCOP - Michigan Cancer Research Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : University of Michigan Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : University of Michigan Health System

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Ann Arbor : University of Michigan Comprehensive Cancer Center

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

Ann Arbor : University of Michigan Health System

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Battle Creek : Battle Creek Health System Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bay City : Bay Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Big Rapids : Mecosta County Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dearborn : Oakwood Cancer Center at Oakwood Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Detroit :

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Detroit : Karmanos Cancer Institute

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Detroit : Investigational Site Number 840005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Detroit : Karmanos Cancer Institute

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Detroit : Josephine Ford Cancer Center at Henry Ford Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Detroit : Wayne State (Karmanos Cancer Institute)

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Detroit :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Detrot :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Escanaba : Green Bay Oncology, Limited - Escanaba

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Genesys Hurley Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Hurley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : McLaren Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Singh and Arora Hematology Oncology, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : Butterworth Hospital at Spectrum Health

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : CCOP - Grand Rapids

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : Lacks Cancer Center at Saint Mary's Health Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grosse Pointe Woods : Van Elslander Cancer Center at St. John Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Iron Mountain : Dickinson County Healthcare System

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jackson : Foote Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : Bronson Methodist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : Borgess Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : West Michigan Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lansing :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Lansing : Breslin Cancer Center at Ingham Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lansing : Sparrow Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lapeer : Great Lakes Cancer Institute - Lapeer Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Livonia : St. Mary Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Monroe : Community Cancer Center of Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Monroe : Mercy Memorial Hospital - Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Clemens : Clemens Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Muskegon : Mercy General Health Partners

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Petoskey : Northern Michigan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pontiac : St. Joseph Mercy Oakland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Port Huron : Mercy Regional Cancer Center at Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Reed City : Spectrum Health Reed City Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Royal Oak : William Beaumont Hospital - Royal Oak Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saginaw : Seton Cancer Institute at Saint Mary's - Saginaw

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Joseph : Lakeside Cancer Specialists, PLLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Joseph : Lakeland Regional Cancer Care Center - St. Joseph

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Southfield : Providence Cancer Institute at Providence Hospital - Southfield Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Traverse City : Munson Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Troy :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Warren : St. John Macomb Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wyoming : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Brainerd : St. Joseph's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Burnsville : Fairview Ridges Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Coon Rapids : Mercy and Unity Cancer Center at Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duluth : Duluth Clinic Cancer Center - Duluth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duluth : CCOP - Duluth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duluth : Miller - Dwan Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Edina : Fairview Southdale Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fridley : Mercy and Unity Cancer Center at Unity Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hutchinson : Hutchinson Area Health Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maplewood : HealthEast Cancer Care at St. John's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maplewood : Minnesota Oncology - Maplewood

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Minneapolis : Hennepin County Medical Center - Minneapolis

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Minneapolis : Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Minneapolis : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

New Ulm : New Ulm Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Robbinsdale : Humphrey Cancer Center at North Memorial Outpatient Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rochester : Mayo Clinic

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Saint Louis Park : CCOP - Metro-Minnesota

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis Park : Park Nicollet Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Paul : United Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sartell : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Shakopee : St. Francis Cancer Center at St. Francis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St Louis Park : Investigational Site Number 840017

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

St Louis Park : Investigational Site Number 840021

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

St. Paul : Regions Hospital Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Stillwater : Lakeview Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Waconia : Ridgeview Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Willmar : Willmar Cancer Center at Rice Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Woodbury : Minnesota Oncology - Woodbury

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jackson : Investigational Site Number 840011

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Jackson : University of Mississippi Cancer Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jackson : Veterans Affairs Medical Center - Jackson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pascagoula : Regional Cancer Center at Singing River Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cape Girardeau : Southeast Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cape Girardeau : Saint Francis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jefferson City : Goldschmidt Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jefferson City : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Kansas City : Investigational Site Number 840016

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kansas City : North Kansas City Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Saint Luke's Cancer Institute at Saint Luke's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Veterans Affairs Medical Center - Kansas City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Heartland Hematology Oncology Associates, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Research Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lee's Summit : Saint Luke's East - Lee's Summit

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Liberty : Parvin Radiation Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Joseph : Heartland Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Joseph : Saint Joseph Oncology, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : CCOP - St. Louis-Cape Girardeau

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : Christian Hospital Northeast Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : David C. Pratt Cancer Center at St. John's Mercy

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : Midwest Hematology Oncology Group, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : Missouri Baptist Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : Saint Louis University Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Springfield : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

St Louis : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

St. Louis : Washington University School of Medicine

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

St. Louis : Washington University School of Medicine

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

St. Louis :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

St. Louis :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Billings : Frontier Cancer Center and Blood Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Billings : CCOP - Montana Cancer Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : Billings Clinic - Downtown

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : Hematology-Oncology Centers of the Northern Rockies - Billings

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : St. Vincent Healthcare Cancer Care Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bozeman : Bozeman Deaconess Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Butte : St. James Healthcare Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Great Falls : Big Sky Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Great Falls : Sletten Cancer Institute at Benefis Healthcare

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Helena : St. Peter's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalispell : Kalispell Medical Oncology at KRMC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalispell : Kalispell Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Missoula : Montana Cancer Center at St. Patrick Hospital and Health Sciences Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Missoula : Montana Cancer Specialists at Montana Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Missoula : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Kearney : Good Samaritan Cancer Center at Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lincoln : Investigational Site Number 840016

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lincoln : Investigational Site Number 840020

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lincoln : Cancer Resource Center - Lincoln

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lincoln : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Omaha : Urology Cancer Center and GU Research Network

A 2 Part Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Omaha :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Omaha : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Omaha : Urology Cancer Center and GU Research Network

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Omaha :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Omaha : Alegant Health Cancer Center at Bergan Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Immanuel Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : CCOP - Missouri Valley Cancer Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Creighton University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Lakeside Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Omaha : Urology Cancer Center, PC

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer

Omaha : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Las Vegas : Comprehensive Cancer Centers of Nevada

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Las Vegas : CCOP - Nevada Cancer Research Foundation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Las Vegas : Nevada Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Las Vegas : University Medical Center of Southern Nevada

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Las Vegas :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Reno : Northern Nevada Radiation Oncology

SpaceOAR System Pivotal Study

Lawrenceville : AdvanceMed Research

A Clinical Research Study for Advanced Prostate Cancer is Currently Enrolling

Lawrenceville : AdvanceMed Research

Prostate Cancer that requires Hormone therapy.

Berlin : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Brick : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

East Orange : Department Of Veterans Affairs NJ Health Care System

A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer

East Orange : Department of Veterans Affairs NJ Health Care System

A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

East Orange : Investigational Site Number 840015

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

East Orange : Investigational Site Number 840017

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Englewood : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Freehold : CentraState Medical Center

SpaceOAR System Pivotal Study

Hamilton : Premier Urology Associates, LLC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Lawrenceville : Premier Urology Associates, LLC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Lawrenceville : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Mount Laurel : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

New Brunswick : Cancer Institute of New Jersey

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

New Brunswick : The Cancer Institute of New Jersey

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

New Brunswick : The Cancer Institute of New Jersey

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

New Brunswick : The Cancer Institute of New Jersey

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Newark : UMDNJ University Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Voorhees : Cooper University Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Voorhees : Delaware Valley Urology

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Voorhees : Cancer Institute of New Jersey at Cooper - Voorhees

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Voorhees : Delaware Valley urology, LLC

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Voorhees : Delaware Valley urology, LLC

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Albuquerque : Urology Group of New Mexico

Prostate Cancer with/without bone metastasis

Albuquerque : Investigational Site Number 840033

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Albuquerque : University of New Mexico Cancer Center

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Albuquerque : Hematology Oncology Associates, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Albuquerque : University of New Mexico Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Albuquerque : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Bronx : Biomedical Research Alliance of New York

Prostate Cancer - Adult Men

Garden City : Advanced Urology Centers of New York, Garden City Central Research Department

For Men with Non-Metastatic Prostate Cancer: A Clinical Trial That Might Interest You

Garden City : Advanced Urology Centers of New York, Garden City Central Research Department

Phase 2, MultiCenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the treatment of Low Risk, Localized (T1c) Prostate Cancer

Albany : The Urological Institute of Northeastern New York

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Albany :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Albany : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Albany : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Bronx : Albert Einstein Medical Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Brooklyn : Brooklyn Urology Research Group

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Brooklyn :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Buffalo : Roswell Park Cancer Institute

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Buffalo :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Buffalo :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

East Setauket : National Translational Research Group, Inc.

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

East Syracuse : CCOP - Hematology-Oncology Associates of Central New York

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elmira : Falck Cancer Center at Arnot Ogden Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Erie, Niagara, and Chautauqua County : Western New York Urology Associates, LLC and D/B/A Cancer Care of WNY

SpaceOAR System Pivotal Study

Garden City : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Garden City :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Garden City :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Garden City : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Garden City : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Lake Success : Clinical Research Alliance, Inc.

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Lake Success : Monter Cancer Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Lake Success : North Shore University Hospital-Monter Cancer Center

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Lake Success : Advanced Radiation Centers of New York

SpaceOAR System Pivotal Study

New Hyde Park : The Arthur Smith Institute for Urology

MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer

New York : Memorial Sloan-Kettering Cancer Center

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

New York : New York Presbyterian Hospital, Weill Cornell Medical College

99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

New York : Memorial Sloan Kettering Cancer Center

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

New York :

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

New York : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

New York : Memorial Sloan-Kettering Cancer Center

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

New York : Investigational Site Number 840022

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

New York : Investigational Site Number 840034

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

New York : Memorial Sloan Kettering Cancer Center

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

New York : Memorial Sloan Kettering Cancer Center

Degarelix Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

New York : University Urology Associates

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

New York :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

New York : Memorial Sloan-Kettering Cancer Center

Molecular Studies and Clinical Correlations in Human Prostatic Disease

New York : Memorial Sloan Kettering Cancer Center

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

New York : NYU Cancer Center

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

New York : Memorial Sloan Kettering Cancer Center

Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

New York :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

New York : Memorial Sloan-Kettering Cancer Center

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

New York : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Oneida : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Poughkeepsie : The Premier Medical Group of the Hudson Valley, PC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Poughkeepsie :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Poughkeepsie :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Rochester : James P. Wilmot Cancer Center at University of Rochester Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rochester : University of Rochester

SpaceOAR System Pivotal Study

Staten Island : Staten Island Urological Research, PC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Staten Island :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Syracuse : SUNY Upstate Medical University

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Syracuse : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Syracuse : SUNY Upstate Medical University

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Syracuse : Associated Medical Professionals of NY, PLLC

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Syracuse :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Syracuse : Associated Medical Professionals of NY

SpaceOAR System Pivotal Study

Syracuse : Upstate Medical University

SpaceOAR System Pivotal Study

Syracuse : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Charlotte : USHIFU

A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

Durham : Duke University

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

Asheville : Mission Hospitals - Memorial Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chapel Hill :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Chapel Hill :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Charlotte : Blumenthal Cancer Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Charlotte : Presbyterian Cancer Center at Presbyterian Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Concord :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Concord : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Durham : Duke Cancer Institute

BKM120 in Metastatic Castration-resistant Prostate Cancer

Durham : Duke Cancer Institute

Pazopanib, Docetaxel, Prednisone Prostate

Durham : Duke University

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Durham :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Goldsboro : Wayne Memorial Hospital, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greensboro : Moses Cone Regional Cancer Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Greensboro :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Greenville : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Hendersonville : Pardee Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Huntersville :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Pinehurst : FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Raleigh :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Raleigh : Investigational Site Number 840024

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Raleigh : Investigational Site Number 840036

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Raleigh :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Raleigh :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Raleigh :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Rutherfordton : Rutherford Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Statesville : Iredell Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Washington : Investigational Site Number 840011

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Wilmington : PMG Research of Wilmington

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Winston Salem : PMG Research of Winston Salem

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Winston-Salem : Forsyth Regional Cancer Center at Forsyth Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bismarck : St. Alexius Medical Center

A research study for patients who have been diagnosed with metastatic, castrate-resistant prostate cancer

Bismarck : Legacy Pharma Research

Prostate Cancer

Bismark : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Akron : Investigational Site Number 840020

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Akron : Investigational Site Number 840026

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Akron : McDowell Cancer Center at Akron General Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Blue Ash : Oncology Hematology Care, Inc.

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Bowling Green : Wood County Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chillicothe : Adena Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cincinati :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Cincinnati :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Cincinnati : Charles M. Barrett Cancer Center at University Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cincinnati : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Cleveland : Cleveland Clinic

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Cleveland :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Cleveland : Investigational Site Number 840023

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Cleveland :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Cleveland :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Cleveland : Cleveland Clinic

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Cleveland : Cleveland Clinic

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Cleveland : University Hospitals Case Medical Center

SpaceOAR System Pivotal Study

Cleveland :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Columbus : The Mark H. Zangmeister Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Columbus : Grant Medical Center Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Mount Carmel Health - West Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Riverside Methodist Hospital Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : CCOP - Columbus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Doctors Hospital at Ohio Health

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Dayton : Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : Grandview Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : Samaritan North Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : CCOP - Dayton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : David L. Rike Cancer Center at Miami Valley Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Delaware : Grady Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elyria : Hematology Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elyria : Community Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Findlay : Blanchard Valley Medical Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Franklin : Middletown Regional Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Wayne Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kettering : Charles F. Kettering Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lancaster : Fairfield Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lima : Lima Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marietta : Strecker Cancer Center at Marietta Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maumee : Northwest Ohio Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Vernon : Knox Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newark : Licking Memorial Cancer Care Program at Licking Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon : Toledo Clinic - Oregon

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon : St. Charles Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portsmouth : Southern Ohio Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Springfield : Community Hospital of Springfield and Clark County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sylvania : Flower Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tiffin : Mercy Hospital of Tiffin

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Medical University of Ohio Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : St. Anne Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : St. Vincent Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Toledo Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : CCOP - Toledo Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Toledo Clinic, Incorporated - Main Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Troy : UVMC Cancer Care Center at Upper Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wauseon : Fulton County Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Westerville : Mount Carmel St. Ann's Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wright-Patterson Afb : United States Air Force Medical Center - Wright-Patterson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Xenia : Ruth G. McMillan Cancer Center at Greene Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Zanesville : Genesis - Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Clackamas : Clackamas Radiation Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Coos Bay : Bay Area Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grants Pass : Three Rivers Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Gresham : Legacy Mount Hood Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Medford : Dubs Cancer Center at Rogue Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Medford : Providence Cancer Center at PMCC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Milwaukie : Providence Milwaukie Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newberg : Providence Newberg Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon City : Willamette Falls Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : OHSU Knight Cancer Institute

BKM120 in Metastatic Castration-resistant Prostate Cancer

Portland : Oregon Health and Science University

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Portland : Oregon Health and Science University Cancer Institute

Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC

Portland : CCOP - Columbia River Oncology Program

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Providence Cancer Center at Providence Portland Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Providence St. Vincent Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Legacy Good Samaritan Hospital & Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Oregon Health & Science University

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Portland : Oregon Health & Science University

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Portland : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Springfield :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Springfield : Oregon Urology Institute

SpaceOAR System Pivotal Study

Tualatin : Legacy Meridian Park Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania

A randomized, double-blind, parallel, placebo-controlled, phase 4, multicenter study to assess efficacy and safety of Vesicare® (solifenacin succinate) to improve urinary continence of subjects after robotic assisted radical prostatectomy. Clinical trial NCT01371994.

Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania

A randomized, double-blind, phase 2, efficacy and safety study of MDV3100 versus bicalutamide in castrate men with metastatic prostate cancer. Clinical trial NCT01288911.

Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania

A randomized, double-blind, phase 3 efficacy trial of PROSTVAC-V/F +/- GM-CSF in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Clinical trial NCT01322490.

Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania

This is a double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in subjects with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen-deprivation therapy. Clinical trial NCT00925600.

Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania

This is an open-label study of the effect of GTx-758 as a secondary hormone therapy on serum PSA and serum free testosterone levels in men with metastatic castration-resistant prostate cancer maintained on androgen deprivation therapy. Clinical trial NCT01615120.

Allentown : Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bala Cynwyd : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Bala Cynwyd : Urologic Consultants of SE PA

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Bala Cynwyd : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Bryn Mawr : Urology Health Specialists, LLC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Bryn Mawr : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Dunmore : Investigational Site Number 840032

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lancaster : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Lancaster :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Lancaster :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Lancaster : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Philadelphia : Thomas Jefferson University / Jefferson Urology Associates

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Philadelphia : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Philadelphia : Thomas Jefferson University

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Philadelphia :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Philadelphia : Thomas Jefferson University

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Philadelphia : Fox Chase Cancer Center

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Philadelphia : Albert Einstein Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Philadelphia :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center

Safety Study of MGA271 in Refractory Cancer

Pittsburgh :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Pittsburgh :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

State College :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Pawtucket : Investigational Site Number 840006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Pawtucket : Investigational Site Number 840007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Anderson : AnMed Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Charleston : Medical University of South Carolina

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Charleston : Medical University of South Carolina

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

Charleston : Hollings Cancer Center at Medical University of South Carolina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Charleston :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Columbia : South Carolina Oncology Associates

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Easley : Cancer Centers of the Carolinas - Easley

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Greenville Hospital System University Medical Center

A 2 Part Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Greenville : Cancer Centers of the Carolinas

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Greenville :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Greenville : Cancer Centers of the Carolinas - Eastside

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Cancer Centers of the Carolinas - Faris Road

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Cancer Centers of the Carolinas - Grove Commons

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : CCOP - Greenville

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Greenville Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Bon Secours St. Francis Health System

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Greenwood : Self Regional Cancer Center at Self Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greer : Matrix Research, LLC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Greer : Cancer Centers of the Carolinas - Greer Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greer : Cancer Centers of the Carolinas - Greer Radiation Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Myrtle Beach :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Myrtle Beach : Investigational Site Number 840037

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Myrtle Beach : Carolina Urologic Research Center

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Myrtle Beach :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Myrtle Beach :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Myrtle Beach : Carolina Urologic Research Center

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Myrtle Beach : Carolina Urologic Research Center

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Myrtle Beach : 21st Century Oncology

SpaceOAR System Pivotal Study

Myrtle Beach : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Seneca : Cancer Centers of the Carolinas - Seneca

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : Cancer Centers of the Carolinas - Spartanburg

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : CCOP - Upstate Carolina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux Falls : Sanford Cancer Center at Sanford USD Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Watertown :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Nashville : Sarah Cannon Research Institute

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

Chattanooga : Investigational Site Number 840025

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Chattanooga : Investigational Site Number 840028

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Chattanooga : Chattanooga Oncology and Hematology Associates

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Chattanooga : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Cookeville : Cookeville Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Germantown : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Knoxville : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Memphis :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Memphis : The West Clinic

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Memphis : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Nashville : Tennessee Oncology, PLLC

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Nashville : Urology Associates, PC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Nashville :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Nashville : Urology Associates, P.C.

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Nashville :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Nashville : Sarah Cannon Research Institute

Safety Study of MGA271 in Refractory Cancer

Nashville :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Nashville : Vanderbilt University

Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer

Amarillo : Harrington Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Amarillo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Austin : The Hospital at Westlake Medical Center

Real Time Microscopic Imaging During Robot Assisted Prostate Cancer Surgery

Bedford : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Carollton : Texas Urology

A 2 Part Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Carrollton : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Corpus Christi : Investigational Site Number 840012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Dallas : Urology Clinics of North Texas

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Dallas :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Dallas :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Dallas : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Fort Sam Houston : Brooke Army Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ft. Worth : Center for Cancer and Blood Disorders, PC

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Galveston : University of Texas Medical Branch

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : University of Texas Vanguard Urologic Research Foundation

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Houston : The University of Texas M D Anderson Cancer Center

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Houston : UT MD Anderson Cancer Center

Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy

Houston : UT MD Anderson Cancer Center

Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone

Houston : UT MD Anderson Cancer Center

Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer

Houston : UT MD Anderson Cancer Center

Maximum Androgen Depletion

Houston : UT MD Anderson Cancer Center

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

Houston : UT MD Anderson Cancer Center

Neoadjuvant Axitinib in Prostate Cancer

Houston : UT MD Anderson Cancer Center

Neoadjuvant Ipilimumab in Prostate Cancer

Houston : Dr. Irving Fishman's Office

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Houston : Dr. Ned Stein's Office

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Houston : Ben Taub General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : Baylor University Medical Center - Houston

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : M. D. Anderson Cancer Center at University of Texas

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : Veterans Affairs Medical Center - Houston

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Houston : University of Texas MD Anderson Cancer Center

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Houston : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Houston : UT MD Anderson Cancer Center

TKI258 in Castrate Resistant Prostate Cancer

Laredo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Round Rock :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

San Antonio : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

San Antonio : Urology San Antonio Research, PA

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

San Antonio : Urology San Antonio Research

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

San Antonio : Urology of San Antonio Research

Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling

San Antonio : University Hospital - San Antonio

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : University of Texas Health Science Center at San Antonio

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : Veterans Affairs Medical Center - San Antonio (Murphy)

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : Cancer Therapy and Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Antonio : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Temple : CCOP - Scott and White Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tomball : Texas Urology Specialists

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

American Fork : American Fork Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar City : Sandra L. Maxwell Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Logan : Logan Regional Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Murray : Jon and Karen Huntsman Cancer Center at Intermountain Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ogden : Val and Ann Browning Cancer Center at McKay-Dee Hospital Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Provo : Utah Valley Regional Medical Center - Provo

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint George : Dixie Regional Medical Center - East Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : Huntsman Cancer Institute at University of Utah

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : LDS Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : Utah Cancer Specialists at UCS Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Salt Lake City : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Salt Lake City : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Fairfax : Virginia Cancer Specialists, PC

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Fairfax : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Fredericksburg : Fredericksburg Oncology, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newport News : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Norfolk :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Norfolk :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Richmond : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Richmond : Virginia Cancer Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Richmond :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Salem : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Virginia Beach : Urology of Virginia

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Virginia Beach :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Virginia Beach : Urology of Virginia, PLLC

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Virginia Beach : Urology of Virginia, PLLC

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Virginia Beach : Urology of Virginia

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Virginia Beach : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Seattle : University of Washington- Seattle Cancer Care Alliance

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

Anacortes : Island Hospital Cancer Care Center at Island Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bellingham : St. Joseph Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bremerton : Olympic Hematology and Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Burien : Seattle Urology Research Center

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Burien : Highline Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Centralia : Providence Centralia Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Everett : Providence Regional Cancer Partnership

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Federal Way : St. Francis Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Issaquah : Swedish Medical Center - Issaquah Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kennewick : Columbia Basin Hematology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kirkland : Cascade Cancer Center at Evergreen Hospital Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Vernon : Skagit Valley Hospital Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Olympia : Providence St. Peter Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Poulsbo : Harrison Poulsbo Hematology and Onocology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Poulsbo : Peninsula Cancer Center

SpaceOAR System Pivotal Study

Puyallup : Good Samaritan Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : University of Washington School of Medicine

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Seattle :

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Seattle : Group Health Cooperative

I-125 Versus Pd-103 for Medium Risk Prostate Cancer

Seattle : VA Puget Sound

I-125 Versus Pd-103 for Medium Risk Prostate Cancer

Seattle : University of Washington

Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC

Seattle : Seattle Cancer Care Alliance

Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy

Seattle : CCOP - Virginia Mason Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Fred Hutchinson Cancer Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Group Health Central Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Harborview Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Minor and James Medical, PLLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Pacific Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Polyclinic First Hill

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Swedish Cancer Institute at Swedish Medical Center - First Hill Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Virginia Mason Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : University Cancer Center at University of Washington Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Seattle : Virginia Mason Hospital

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Seattle : Virginia Mason Medical Center

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Seattle :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Seattle :

Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Seattle : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Sedro-Woolley : North Puget Oncology at United General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spokane : Cancer Care Northwest - Spokane South

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spokane : Evergreen Hematology and Oncology, PS

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spokane : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Tacoma : Allenmore Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : CCOP - Northwest

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : St. Clare Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : Franciscan Cancer Center at St. Joseph Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : MultiCare Regional Cancer Center at Tacoma General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Vancouver : Legacy Salmon Creek Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Vancouver : Southwest Washington Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wenatchee : Wenatchee Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : St. Mary's Hospital Medical Center - Green Bay

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : St. Vincent Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : Green Bay Oncology, Limited at St. Mary's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

La Crosse : Gundersen Lutheran Center for Cancer and Blood

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Madison : University of Wisconsin

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Madison :

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Madison : University of Wisconsin Carbone Cancer Center

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Madison : University of Wisconsin Carbone Cancer Center

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Madison : University of Wisconsin Carbone Cancer Center

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

Madison :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Madison :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Madison : University of Wisconsin Carbone Cancer Center

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Manitowoc : Holy Family Memorial Medical Center Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Milwaukee :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Oconto Falls : Green Bay Oncology, Limited - Oconto Falls

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sheboygan : St. Nicholas Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sturgeon Bay : Green Bay Oncology, Limited - Sturgeon Bay

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Casper : Rocky Mountain Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Buenos Aires : Investigational Site Number 032002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Rosario : Investigational Site Number 032001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Salta : Investigational Site Number 032003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Santa Fe : Investigational Site Number 032004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Adelaide : Investigational Site Number 036014

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Albury : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bankstown : Investigational Site Number 036013

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bankstown : Investigational Site Number 036016

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Box Hill : Investigational Site Number 036010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Brisbane : Haematology and Oncology Clinics of Australia

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Camperdown : Investigational Site Number 036012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Camperdown : Investigational Site Number 036008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Camperdown : Royal Prince Alfred Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Coffs Harbour : Investigational Site Number 036008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Coffs Harbour : Investigational Site Number 036015

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Concord : Investigational Site Number 036001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Concord : Investigational Site Number 036001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Darlinghurst : St Vincent's Hospital, Sydney

A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer

Elizabeth Vale : Investigational Site Number 036015

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Fitzroy : Investigational Site Number 036009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Fitzroy : Investigational Site Number 036017

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Garran : Investigational Site Number 036007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Garran : The Canberra Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Heidelberg : Austin Health

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Heidelberg West : Investigational Site Number 036005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Herston : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Herston : Investigational Site Number 036003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Hobart : Royal Hobart Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Hobart : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Hornsby : Investigational Site Number 036010

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kogarah : St George Public Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Kogarah : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Kurralta Park : Investigational Site Number 036012

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kurralta Park : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Malvern : Investigational Site Number 036002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Milton : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Parkville : Investigational Site Number 036002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Port Macquarie : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Randwick :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Randwick : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Richmond : Epworth Healthcare

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Ringwood East : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Saint Leonards : Royal North Shore Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

South Brisbane : Investigational Site Number 036006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

South Brisbane : Investigational Site Number 036009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

South Brisbane : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Subiaco : Investigational Site Number 036016

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Subiaco : Investigational Site Number 036011

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Toowoomba : Radiation Oncology Queensland

PROstate Cancer Imaging, Treatment and Toxicity (PROCITT)

Wahroonga : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Wahroonga : Investigational Site Number 036003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Wahroonga : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Westmead : Westmead Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Westmead : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Wodonga : Investigational Site Number 036004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Wodonga : Investigational Site Number 036013

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Wondonga : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Woodville South : The Queen Elizabeth Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Woolloongabba : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Graz : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Innsbruck : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Linz : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Salzburg : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

St Poelten : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

VÃ¶cklabruck : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wein : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Wels : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wien : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wien : Ludwig Boltzmann-Institute for Applied Cancer Research

Sipuleucel-T Manufacturing Demonstration Study

Wien : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Minsk : Investigational Site Number 112002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Minsk : Investigational Site Number 112001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Vitebsk : Investigational Site Number 112004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Aalst : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Aalst : Onze-Lieve-Vrouwziekenhuis

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Aalst : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Antwerpen : Investigational Site Number 056007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Antwerpen : Site: 5

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Antwerpen : Site: 9

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Antwerpen : Site: 14

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Antwerpen : Site: 4

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Antwerpen : Site: 8

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Bonheiden : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bonheiden : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Brasschaat : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brugge : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brugge : AZ Sint-Jan AV

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Brussel : Investigational Site Number 056008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Brussel : Site: 13

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Brussels : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bruxelle : Hôpital Erasme

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bruxelles : Investigational Site Number 056001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bruxelles : Investigational Site Number 056002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bruxelles : Site: 23

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Bruxelles : Université Catholique de Louvain

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Charleroi : Investigational Site Number 056009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Edegem : Investigational Site Number 056014

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Eupen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Gent : Investigational Site Number 056003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Gent : Site: 11

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Gent : UZ Gent

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Gent : AZ Maria Middelares

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Gent : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Ghent : University Hospital Ghent

The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate

Gilly : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Haine-Saint-Paul : Investigational Site Number 056016

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hasselt : Investigational Site Number 056005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ieper : Site: 21

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Ieper : Regionaal Ziekenhuis Jan Yperman VZW

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Izegem : Site: 20

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Kortijk : Site: 25

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Kortrijk : AZ Groeninge - Campus Sint-Maarten

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Leuven : University Hospitals Leuven

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Leuven : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Libramont : Investigational Site Number 056010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Liège : Investigational Site Number 056013

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Liège : Site: 38

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Liège : CHU de Liège

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Liège : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Mechelen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Merksem : Site: 33

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Namur : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Oostende : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Oostende : Site: 31

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Oostende : AZ Damiaan

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Ottignies : Investigational Site Number 056011

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Oudenaarde : Site: 17

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Roeselare : Investigational Site Number 056004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Roeselare : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Sint Truiden : Site: 37

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Sint-Niklaas : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Tienen : Site: 18

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Turnhout : Investigational Site Number 056006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Turnhout : Site: 1

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Verviers : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Yvoir : Investigational Site Number 056012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sarajevo : Klinicki Centar Univerziteta Sarajevo - Klinika za gastroenterohepatologiju

Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

Curitiba : Investigational Site Number 004

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Fortaleza : Investigational Site Number 076016

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ijui : Investigational Site Number 076012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Mogi Das Cruzes : Investigational Site Number 076015

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Passo Fundo : Investigational Site Number 076006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Porto Alegre : Investigational Site Number 076014

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Porto Alegre : Investigational Site Number 076001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Porto Alegre : Investigational Site Number 076002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Porto Alegre : Investigational Site Number 005

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Rio De Janeiro : Investigational Site Number 076010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Rio De Janeiro : Investigational Site Number 076004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Rio de Janeiro : Multi-Imagem and CDPI - Clínica de Diagnóstico por Imagem

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Salvador : Investigational Site Number 076007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Santo Andre : Investigational Site Number 001

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Sao Jose Do Rio Preto : Investigational Site Number 076003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Jose Do Rio Preto : Investigational Site Number 076009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076013

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

São Paulo : Investigational Site Number 002

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Uberlandia : Investigational Site Number 076003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Pleven :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Plovdiv : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Plovdiv :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Shumen :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Sofia : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Varna :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Toronto, Ontario : Princess Margaret Hospital

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

Abbotsford : Dr. George Vrabec

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Abbottsford : Site Reference ID/Investigator# 56448

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Barrie : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Barrie : The Male/Female Health and Research Centre

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Barrie : Site Reference ID/Investigator# 56450

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Brampton : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Brampton : Dr. Stanley Flax

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Brampton : Dr. Jonathan Giddens

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Brampton : Site Reference ID/Investigator# 54902

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Brantford : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Brantford : Brantford Urology Research

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Brantford : Site Reference ID/Investigator# 54543

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Burlington : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Burlington : G. Kenneth Jansz Medicine Professional Corporation

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Burlington : Site Reference ID/Investigator# 54904

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Burlington : Site Reference ID/Investigator# 57123

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Calgary : Tom Baker Cancer Centre

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Calgary : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Chicoutimi : Site Reference ID/Investigator# 57032

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Edmonton : Cross Cancer Institute

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Edmonton :

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Edmonton : Cross Cancer Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Edmonton : Cross Cancer Institute

Seed Movement in Prostate Brachytherapy Implants: Clinical Measurement and Dosimetric Consequences

Gatineau : Hôpital de Gatineau

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Granby : Site Reference ID/Investigator# 55512

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Greenfield Park : Investigational Site Number 124002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Greenfield Park : Urology South Shore Research

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Greenfield Park : Urology South Shore Research Inc.

Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year

Greenfield Park : Site Reference ID/Investigator# 56447

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Guelph : Dr. Eric Hirshberg

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Guelph : Site Reference ID/Investigator# 56452

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Halifax : QEII Health Sciences Center

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Halifax : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Hamilton : Juravinski Cancer Centre at Hamilton Health Sciences

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Hamilton : Juravinski Cancer Centre

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Kelowna : BCCA - Cancer Centre for the Southern Interior

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Kelowna : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Kelowna : Southern Interior Medical Research Inc.

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Kelowna : Site Reference ID/Investigator# 56446

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Kelowna :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Kingston : Cancer Centre of Southeastern Ontario at Kingston

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Kingston : Kingston Regional Cancer Centre

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Kitchener : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Laval : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Laval : Polyclinique Med Concorde

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Laval : Site Reference ID/Investigator# 54903

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

London : London Regional Cancer Program

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

London : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

London : Investigational Site Number 124002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

London : Site Reference ID/Investigator# 54907

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

London : London Regional Cancer Program

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

London : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Mississauga : Investigational Site Number 124007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Moncton : Investigational Site Number 124005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Montreal : Centre hospitalier de l'Universite de Montreal (CHUM)

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Montreal : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Montreal : CHUM-Notre- Dame

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Montreal : Hôpital Maisonneuve-Rosemont

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Montreal : Jewish General Hospital

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Montreal : Investigational Site Number 124003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Montreal : Site Reference ID/Investigator# 74493

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Montreal : Site Reference ID/Investigator# 75313

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Montréal : CHUM-Hospital Notre-Dame

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Newmarket : Dr. Morrie Liquornik

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Newmarket : Site Reference ID/Investigator# 54909

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

North York : Toronto Urology Clinical Study Group

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

North York : Site Reference ID/Investigator# 54908

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Oakville : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Oakville : Dr. Richard Casey

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Oakville : Site Reference ID/Investigator# 54542

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Oshawa : Investigational Site Number 124001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Oshawa : R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health Oshawa

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Oshawa : Site Reference ID/Investigator# 61303

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Ottawa : Investigational Site Number 124003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ottawa : The Ottawa Hospital Regional Cancer Centre

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Owen Sound : Investigational Site Number 124005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Owen Sound : Dr. Todd Webster

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Owensound : Site Reference ID/Investigator# 56449

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Peterborough : Site Reference ID/Investigator# 56917

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Peterborough : Site Reference ID/Investigator# 61722

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Pointe-Claire : Site Reference ID/Investigator# 56445

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Quebec : Investigational Site Number 124004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Quebec : CHUQ- Hotel-Dieu de Quebec

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Regina : Allan Blair Cancer Centre

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Richmond Hill : Site Reference ID/Investigator# 64145

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Scarborough : Dr. Allan Abramovitch

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Scarborough : Site Reference ID/Investigator# 54906

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Scarborough : Site Reference ID/Investigator# 54905

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Sherbrooke : CHUS - Hôpital Fleurimont - Sherbrooke

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Surrey : Andreou Research

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Surrey, : Site Reference ID/Investigator# 56443

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Toronto : Univ. Health Network-Princess Margaret Hospital

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Toronto : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Toronto : Investigational Site Number 124006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Toronto : Sunnybrook Health Sciences Centre

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Toronto : Sunnybrook Health Sciences Centre, Odette Cancer Centre

Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer

Toronto : Site Reference ID/Investigator# 56451

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Toronto : Site Reference ID/Investigator# 57762

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Toronto : Site Reference ID/Investigator# 60843

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Toronto : Site Reference ID/Investigator# 56444

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Toronto :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Toronto :

Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Trois-Rivieres : Site Reference ID/Investigator# 56453

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Trois-Rivières : Centre Hospitalier régional de Trois-Rivières

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Val d'Or : Site Reference ID/Investigator# 55513

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Vancouver : BCCA - Vancouver Cancer Centre

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Vancouver :

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Vancouver : British Columbia Cancer Agency

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Vancouver : BC Cancer Agency

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Vancouver : BCCA - Vancouver Cancer Centre

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Vancouver :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Vancouver :

Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Victoria : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Victoria : Dr. Steinhoff Clinical Research

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Santiago : Investigational Site Number 152005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Santiago : Investigational Site Number 152002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Santiago : Investigational Site Number 152004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Viña Del Mar : Investigational Site Number 152001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Beijing : Investigational Site Number 156005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Beijing : Peking University People's Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Beijing : Beijing Hospital of Ministry of Health

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Beijing : Peking Union Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Beijing : Peking University 3rd Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Beijing :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Changchun : 1st Hospital of Jilin University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Changsha : Hunan Cancer Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Changsha : Hunan Province People's Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Chengdu : People's Hospital of Sichuan

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Chengdu :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Chongqing :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Guangzhou :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Hangzhou : 2nd Hospital Affiliated to Zhejiang University Medical School

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Hangzhou :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Jinan :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Lanzhou : 1st Hospital of Lanzhou University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Nanchang : 1st Affiliated Hospital of Nanchang University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Nanjing : 1st Affiliated Hospital of Nanjing Medical University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Nanjing : Drum Tower Hospital Affiliated to Nanjing University Medical School

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Shanghai : Investigational Site Number 156002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Shanghai : Investigational Site Number 156003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Shanghai : Investigational Site Number 156004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Shanghai : Shanghai 5th People's Hospital affilicated to Fudan University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Shanghai : Shanghai Changhai Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Shanghai : Fudan University Shanghai Cancer Center

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Shanghai : Huashan Hospital of Fudan University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Shanghai :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Shenyang : 1st Hospital Affiliated to China Medical University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Suzhou : 2nd Hospital Affiliated to Suzhou University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Tianjin : 2nd Hospital of Tianjin Medical University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Tianjin :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Wuchang : Renmin Hospital of Wuhan University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Wuhan : Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Wuhan : Zhongnan Hospital of Wuhan University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Wuhan :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Wuxi : 1st People's Hospital of Wuxi

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Benesov : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Brno : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Brno : Investigational Site Number 203002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Hradec Králové : Fakultni nemo Hradec Králové

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Jindrichuv Hradec : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Kromeriz : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Liberec : Krajská nemocnice Liberec a.s.

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Novy Jicin : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Novy Jicin : Investigational Site Number 203003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Olomouc : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Olomouc : Investigational Site Number 203001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Olomouc : University Hospital Olomouc

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Praha 2 : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Praha 2 : Investigational Site Number 203004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Praha 4 : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Praha 6 : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Usti nad Labem : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Zlin : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Zlín : Krajská nemo. T.Bati, a. s.

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Znojmo : Nemocnice Znojmo

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Znojmo : Oddeleni Radiacni a Klinicke Onkologie Nemocnice Znojmo

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Aalborg : Aalborg Sygehus

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Ålborg : Investigational Site Number 208004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Fredericia : Fredericia Hospital, Sygehus Lillebaelt

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Herlev : Investigational Site Number 208002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Herlev : Herlev Hospital

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Holstebro : Holstebro Sygehus

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Kobenhavn : Rigshospitalet

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

København Ø : Investigational Site Number 208001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Odense C : Investigational Site Number 208003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Viborg : Regionhospitalet Viborg

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Helsinki : Investigational Site Number 246002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Helsinki : Docrates clinic

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Helsinki : Helsinki University Central Hospital

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Helsinki : Helsinki University Central Hospital

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Joensuu : Pohjois-Karjalan keskussairaala

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Kuopio : Investigational Site Number 246001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kuopio : Kuopio University Hospital

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Kuopio : Kuopio University Hospital

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Tampere : Tampere University Hospital

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Tampere : Tampere University Hospital

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Turku : Investigational Site Number 246003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Aix en Provence : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Aix en Provence cedex 01 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Amiens : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Angers : CHRU Angers

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Angers : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Athis Mons : Centre Hospitalier d'Athis Mons site Caron

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Aubervilliers : Hopital Tenon

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Avignon : Investigational Site Number 250005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Avignon : Clinique Rhone Durance

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bayonne : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

BesanÃ§on Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Besancon : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Besançon : CHU Saint-Jacques

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Besancon Cedex : Investigational Site Number 250010

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Bordeaux : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bordeaux : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bordeaux Cedex : Investigational Site Number 250002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bourg en Bresse : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brive la Gaillarde : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Caen Cedex 05 : Investigational Site Number 250006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Caen cedex 05 : Centre François Baclesse

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Clermont Ferrand : Centre Hospitalier Laennec

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Clermont Ferrand : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Colmar Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Dijon : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Dijon : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Evry : Ramsay Sante

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Hyeres : Investigational Site Number 250008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

La Roche Sur Yon : Investigational Site Number 250001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

La Roche sur Yon : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

La Seyne Sur Mer : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Le Mans : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Le Mans Cedex 9 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lille : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Longjumeau cedex 1 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lyon : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Lyon : Investigational Site Number 250005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lyon : Groupement hospitalier Edouard Herriot

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Lyon cédex 08 : Centre Léon Bérard

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Marseille : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Marseille : CHU Nord

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Marseille : Hopital de la Conception

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Marseille : Cabinet Médical 65 prado

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Marseille : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Melun : Polyclinique Saint-Jean

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Mont de Marsan : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Montauban : Clinique du Pont de Chaume

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Montpellier : Clinique Beausoleil

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nancy : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Nancy : Centre d'Urologie de Nancy

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nanterre : Hôpital Max Fourestier

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nantes : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Nantes Cedex 2 : Investigational Site Number 250002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Nice Cedex 2 : Centre Antoine Lacassagne

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Nimes : Investigational Site Number 250004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Nîmes : Groupe hospitalo-universitaire Caremeau

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Niort : Centre Hospitalier Georges Renon

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Paris : Investigational Site Number 250010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Paris : Hôpital Européen Georges Pompidou - Service Oncologie Médicale

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Paris : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Paris Cedex 05 : Investigational Site Number 250003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Paris Cedex 05 : Institut Curie

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Paris Cedex 10 : Investigational Site Number 250004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Paris Cedex 15 : Investigational Site Number 250001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Paris Cedex 20 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Paris Cedex 5 : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Pierre Benite : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Ploemeur : Clinique du Ter

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Poitiers Cedex : Investigational Site Number 250007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Poitiers Cedex : Centre Hospitalier Universitaire de Poitiers Hôpital de la Milétrie

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Pontoise : Clinic De L'Europe

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Pontoise Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Pringy Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Reims : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Reims : Investigational Site Number 250007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Reims : Investigational Site Number 250009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Reims : Institut Jean-Godinot

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Reims Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rennes : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rennes : Hopital Pontchaillou

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Rennes : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Rouen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint Brieuc Cedex : Investigational Site Number 250006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint Herblain : Institut de Cancérologie de l'Ouest - René Gauducheau

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Saint Quentin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint-Herblain : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Soissons Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Soyaux : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Strasbourg : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Suresnes : Investigational Site Number 250008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Suresnes :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Suresnes : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Toulon : Clinique Saint Michel

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Toulouse : Clinique St Jean Languedoc

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Toulouse Cedex : Investigational Site Number 250003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Toulouse Cedex 03 : Investigational Site Number 250011

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Tours : Hopital Bretonneau

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Vandoeuvre les Nancy : CHU Brabois

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Vichy cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villefranche Sur Saone Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villejuif : Investigational Site Number 250001

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Villejuif : Investigational Site Number 250009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Villejuif : Institut Gustave Roussy

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Villejuif Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villejuif Cedex : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Aachen : Investigational Site Number 276003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Aachen : Investigational Site Number 276003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Augsburg : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bad Bergzabern : Praxis Dr. Schlichter

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bautzen : Praxis Dr. Markus Hentschel

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Berlin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Berlin : Investigational Site Number 276005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Braunschweig : Urologie im Schlosscarree

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bremerhaven : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bremerhaven : Praxis Dr. Ahmad Haider

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Chemnitz : Urologie Chemnitz

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Chemnitz : Praxis Dr. Krieger

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Dachau : Gemeinschaftspraxis fur Urologie

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Dinslaken : Klinikpraxis fur Urologie

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Dresden : Investigational Site Number 276007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Düsseldorf : Investigational Site Number 276004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Düsseldorf : Investigational Site Number 276001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Erlangen : Investigational Site Number 276001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Erlangen : Investigational Site Number 276004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Freiburg im Breisgau : Clinic SanaFontis

Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

Goslar : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Halle/Saale : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Hamburg : Investigational Site Number 276005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hamburg : Investigational Site Number 276011

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hamburg : Universitaetsklinik Hamburg-Eppendorf, Med. Klinik II Onkologie, Haematologie

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Hamburg : Praxis Dr. Schönfelder

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Homburg : Investigational Site Number 276010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Homburg : Investigational Site Number 276002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

KÃ¶ln : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Kassel : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Kiel : Gemeinschaftspraxis Urologie

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Kiel : Urologische Gemeinschaftspraxis

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Kirchheim : Gemeinshaftspraxis Rudolph & Wörner

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Koln : Praxis Dr. Thomas Harms

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Leipzig : Vituro

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Mannheim : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Marburg : Praxis Alexander von Keitz

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

München : Investigational Site Number 276006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

München : Investigational Site Number 276006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Neunkirchen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Nienburg : Praxis Dr. Peczat

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nürtingen : Investigational Site Number 276012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Planegg : UCM GmbH

Treatment of Prostate Cancer With Firmagon®

Planneg : Studienzentrum München-Planegg

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Reutlingen : Urologische Gemeinschaftspraxis

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Stralsund : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Tostedt : Praxis Dr. Jan Franz

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Tübingen : Investigational Site Number 276008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

WÃ¼rselen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wuppertal : Investigational Site Number 276002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Wuppertal : Praxis fur Urologie

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Alexandroupoli : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Athens : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Athens : Ippokrateio Hospital of Athens

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Athens : "Agios Savas" Anticancer-Oncology Hospital of Athens

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Athens : Korgialenio-Benakio

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Herakleion : Pe. Pa.G.N:I Hospital

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Heraklion : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Kalamata : General hospital of Kalamata

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Larissa : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Larissa : University Hospital of Larissa

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Marousi : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Patra : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Patras : University General Hospital of Patras

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Thessaloniki : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Thessaloniki : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Thessaloniki : "G. Gennimtas" General Hospital of Thessaloniki

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Thessaloniki : Papageorgiou General Hospital of Thessaloniki

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Baja : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Budapest : Jahn Ferenc South Pest Hospital, Department of Urology

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Budapest : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Budapest : Investigational Site Number 348001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Budapest : Investigational Site Number 348004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Budapest : Investigational Site Number 348005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Budapest : Országos Onkológiai Intézet

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Budapest : Semmelweis Egyetem Általános Orvostudományi Kar

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Gyor : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Gyula : Pándy Kálmán Megyei Kórház

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Kiskunhalas : Kiskunhalasi Semmelweis Kórház Kht.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Miskolc : Investigational Site Number 348006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Miskolc : Borsod Abaúj Zemplén Megyei Kórház és Egyetemi Oktató Kórház

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Miskolc : Miskolci Semmelweis Ignác Egészségügyi Központ és Egyetemi Oktató Kórház Nonprofit Kft

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nyiregyhaza : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Pécs : Investigational Site Number 348003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sopron : Soproni Erzsébet Oktató Kórház

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Szeged : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Ahmedabad : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Aurangabad : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Ludhiana : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Madurai : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Nashik : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

New Delhi : Vardhaman Mahavir Medical College And Safdarjung Hospital

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Cork : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Dublin : Beacon Hospital

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Dublin : Beaumont Hospital

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Dublin : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Galway : University College Hospital

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Haifa : Bnai Zion medical center

A Novel 3D Navigation Technology for Improved TRUS Prostate Biopsy

Kfar Saba : Investigational Site Number 376004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Petah-Tikva : Investigational Site Number 376003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tel Aviv : Investigational Site Number 376002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tel Aviv : Ichilov Medical Center

Evaluation of the Safety and Efficacy of the BioProtect Balloon in Prostate Cancer Subjects Undergoing Radiotherapy

Tel Hashomer : Sheba Medical Center

Safety Evaluation of ExAblate MRgFUS for Prostate Cancer

Ancona : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Arezzo : Investigational Site Number 380001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Avellino : Medical Consulting Center S.r.l.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Aviano : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bari : Investigational Site Number 380004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Brindisi : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Catanzaro : Azienda Ospedaliera Mater Domini di Catanzaro

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

CefalÃ¹ PA : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Cesena : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Cremona : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Faenza : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Genova : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Lugo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Meldola : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Milano : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Napoli : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Novara : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Orbassano : Investigational Site Number 380003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Orbassano : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Padova : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Padova : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Pavia : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Pisa : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Ravenna : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Reggio Calabria : Azienda Ospedaliera "Bianchi-Melacrino-Morelli"

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Rimini : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Roma : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Roma : Investigational Site Number 380005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Roma : Istituto Nazionale Tumori "Regina Elena"

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Rome : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Rozzano : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Terni : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Torino : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Torino : Azienda Ospedaliero Universitaria "San Giovanni Battista di Torino"

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Torino : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Trento : Investigational Site Number 380002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Asahi :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Asahi :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Bunkyo-Ku : Investigational Site Number 392001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Chiba-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Chiba-Shi : Investigational Site Number 392003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Fukuoka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Fukuoka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Fukuoka-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Gifu :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Itabashi-ku :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Kanazawa :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Kanazawa :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Kanazawa-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Kashiwa :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Kashiwa-Shi : Investigational Site Number 392006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kita-adachi-gun :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Kita-Gun :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Kita-Gun :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Koto-Ku : Investigational Site Number 392005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kuki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Kuki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Kurashiki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Kurashiki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Maebashi :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Maebashi N/A :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Maebashi N/A :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Maebashi-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Matsuyama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Matsuyama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Miki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Miki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Mitaka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Mitaka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Nagoya-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Nigata-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Niigata :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Niigata :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Osaka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Osaka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Osaka Sayama-Shi : Investigational Site Number 392002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Osaka-City :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Osaka-City :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Osaka-Sayama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Osaka-Sayama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Osaka-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Osaka-Shi : Investigational Site Number 392004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Sagamihara :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Sagamihara :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Sakura :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Sakura :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Sakura-Shi :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Sakura-Shi :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Sapporo :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Sapporo :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Sapporo-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Sendai-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Shinjuku-ku :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Shizuoka-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Suita-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Tokyo :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Yokohama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Yokohama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Yokohama-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Yokosuka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Yokosuka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Busan :

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Cheongju-Si :

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Seognam-Si, Kyungki-Do :

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Seongnam : Investigational Site Number 410003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Seongnam : Seoul National University Bundang Hospital

Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy

Seoul : Investigational Site Number 410004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Seoul : Investigational Site Number 410005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Seoul : Investigational Site Number 410002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Seoul : Investigational Site Number 410001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Daugavpils :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Jelgava : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Riga : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Riga :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Kuala Lumpur :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Kuala Lumpur N/A :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Acapulco : Investigational Site Number 484007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Aguascalientes : Investigational Site Number 484008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

D.f. : Investigational Site Number 484003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Distrito Federal : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Guadalajara : Investigational Site Number 484004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Merida : Investigational Site Number 484009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Queretaro : Investigational Site Number 484005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

San Luis Potosi : Investigational Site Number 484002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tlalpan : Instituto Nacional de Cancerologia

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Zapopan : Investigational Site Number 484006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Amstelveen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Amsterdam : AMC

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Arnhem : Investigational Site Number 528005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Blaricum : Investigational Site Number 528003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Den Haag : MC Haaglanden

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Dordrecht : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Eindhoven : Catharina ziekenhuis

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Enschede : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Groningen : UMC Groningen

Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients

Groningen : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Hoofddorp : Investigational Site Number 528004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Leiden : Diaconessenhuis Leiden

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Leiderdorp : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Nieuwegein : St. Antonius Hospital

Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.

Nieuwegein : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Nijmegen : Investigational Site Number 528002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Nijmegen : UMC Nijmegen

Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients

Nijmegen : Radboud University Nijmegen Medical Centre

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Nijmegen : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Purmerend : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Roosendaal : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rotterdam : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Utrecht : Diakonessenhuis

Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.

Utrecht : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Vlissingen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Woerden : Zuwe Hofpoort Ziekenhuis Woerden, Netherlands

Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.

Zutphen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Zwolle : Investigational Site Number 528001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Zwolle : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Christchurch : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Takapuna, North Shore City : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Tauranga : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Whangarei : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Bergen : Haukeland Universitetssykehus

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Gjettum : Vestre Viken HF, Sykehuset Asker og Baerum

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Oslo : Oslo Universitetssykehus, Aker

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Oslo : Jon R Iversen

Treatment of Prostate Cancer With Docetaxel + Hormonal Treatment Versus Hormonal Treatment in Patients Treated With Radical Radiotherapy

Trondheim : Norwegian University of Science and Technology

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Arequipa : Investigational Site Number 604003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Bialystok : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bydgoszcz : Investigational Site Number 616002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Gdansk : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Gdansk : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Gdansk : Investigational Site Number 616001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Gdynia : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Katowice : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Koscierzyna : Investigational Site Number 616003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Koszalin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Krakow : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lodz : Investigational Site Number 616005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lubin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lubin : Investigational Site Number 616006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lublin : SPSK1 Klinika Hematologii

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Myslowice : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Olsztyn : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Olsztyn : Investigational Site Number 616002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Opole : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Poznan : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Poznan : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Poznan : Investigational Site Number 616004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Rybnik : Investigational Site Number 616001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Siedlce : Investigational Site Number 616005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Slupsk : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Szczecin : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Torun : Investigational Site Number 616004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Walbrzych : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Warsaw :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Warszawa : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Wroclaw : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Wroclaw : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Coimbra : Investigational Site Number 620003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lisboa : Investigational Site Number 620004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lisboa : Investigational Site Number 620005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Porto : Investigational Site Number 620001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Porto : Investigational Site Number 620002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Ponce : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Alba Iulia : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Alba Iulia : Investigational Site Number 642005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Baia Mare : Investigational Site Number 642006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Baia Mare : Investigational Site Number 642004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Baia-Mare : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brasov : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bucharest : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bucharest : Investigational Site Number 642008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Bucharest :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Bucuresti : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bucuresti : Investigational Site Number 642008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bucuresti : Investigational Site Number 642009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bucuresti : Investigational Site Number 642005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Bucuresti : Centrul de Diagnostic si Tratament Euromedic Fundeni

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Cluj Napoca : Investigational Site Number 642001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Cluj-Napoca : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Craiova :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Focsani : Investigational Site Number 642012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hunedoara : Investigational Site Number 642007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hunedoara : Investigational Site Number 642007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Onesti : Investigational Site Number 642013

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Oradea : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Ramnicu Valcea : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Targu Mures : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Timisoara : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Arkhangelsk :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Ekaterinburg : Investigational Site Number 643009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ekaterinburg : Investigational Site Number 643004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Ekaterinburg :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Ivanovo : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Moscow : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Moscow : Investigational Site Number 643004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Moscow : Investigational Site Number 643005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Moscow : Investigational Site Number 643006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Moscow : Investigational Site Number 643007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Moscow : Investigational Site Number 643008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Moscow :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Moscow N/A :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Nizhny Novgorod : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Obninsk : Investigational Site Number 643008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Omsk : Investigational Site Number 643003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Pyatigorsk : Investigational Site Number 643002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Pyatigorsk :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Rostov-na-Dony : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Rostov-On-Don :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Ryazan : Investigational Site Number 643007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Sochi :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

St.Petersburg : Investigational Site Number 643001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

St.Petersburg : Investigational Site Number 643010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Stavropol :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

St-Petersburg : Investigational Site Number 643005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tomsk : Investigational Site Number 643001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tula : Investigational Site Number 643003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ufa :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Yaroslavl : Investigational Site Number 643006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Yoshkar-Ola :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Riyadh : King Faisal Specialist Hospital and Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bosany : VEBMED, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bratislava : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Bratislava : URO clinic, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bratislava : Univerzitna nemocnica Bratislava

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bratislava : CUIMED, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Galanta : Poliklinika Galanta

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Kosice : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Kosice : MEDICONA s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Levice : UROCENTRUM LEVICE, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Malacky : Poliklinika Malacky

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Martin : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Martin : Univerzitna nemocnica Martin

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nitra : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Nitra : UROEXAM, spol. s r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Povazska Bystrica : CENTRUM UROLOGIE Povazska Bystrica s.r.o

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Presov : MILAB, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Sala : UROCENTRUM SALA, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Skalica : Nemocnica s poliklinikou Skalica, a.s.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Topolcany : M & M & M, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Trencin : PRIVATNA UROLOGICKA AMBULANCIA s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Vrable : UROREX, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Celje : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Ljubljana : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Slovenj Gradec : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Cape Town : Investigational Site Number 710003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cape Town : Department of Urology, Tygerberg Hospital

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Cape Town : New Grootte Schuur Hospital, Division of Urology

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Cape Town : Paarl Medical Centre

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Cape Town : Vergelegen Medi-Clinic

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Durban : Investigational Site Number 710002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Eastern Cape : Dr JCM Bahlmann

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Gauteng : Clinical Trial Unit, Room 2-54, Prinshof Medical Campus

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Gauteng : Clinresco Centres (Pty) Ltd

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Gauteng : Pretoria Urology Hospital

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

George : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Johannesburg : Investigational Site Number 710004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Johannesburg : Investigational Site Number 710005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Johannesburg : East Rand Urology Research Unit, Clinix Private Clinic

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Kempton Park : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Klerksdorp : Wilmed Park Hospital

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Paarl : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Port Elizabeth : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Pretoria : Investigational Site Number 710001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Tygerberg : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Badalona : Investigational Site Number 724003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Barcelona : Investigational Site Number 724001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Barcelona : Investigational Site Number 724007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Barcelona : Investigational Site Number 724001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Barcelona : Investigational Site Number 724002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Barcelona : Hospital Clinic i Provincial de Barcelona

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Barcelona : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Barcelona : Fundación IMOR Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Barcelona : H. de la Santa Creu i Sant Pau Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Hospitalet De Llobregat : Investigational Site Number 724003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Hospitalet de Llobregat : ICO Institut Català d'Oncologia-Hospitalet Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

La Coruna : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

La Laguna : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Madrid : Investigational Site Number 724002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Madrid : Investigational Site Number 724008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Madrid : Investigational Site Number 724004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Madrid : Investigational Site Number 724005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Madrid : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Madrid : H. Ramón y Cajal Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Majadahonda : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Málaga : Investigational Site Number 724006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Manresa : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Palma De Mallorca : Investigational Site Number 724005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Palma de Mallorca : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Sabadell : Investigational Site Number 724004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

San Cristobal de la Laguna Santa Cruz : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

San Sebastián : Instituto Oncológico Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Santiago De Compostela : Investigational Site Number 724006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Santiago de Compostela : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Santiago de Compostela : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Sevilla : Investigational Site Number 724007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Valencia : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Valencia : IVO Instituto Valenciano de Oncología Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Valencia : Private practice, La Cañada, Paterna Updated

Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State

Gotenborg : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Malmo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Malmö : Investigational Site Number 752003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Malmoe : Urology Dep. Skane Univeristy Hospital

Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer

Orebro : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Stockholm : Investigational Site Number 752002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Stockholm : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Umea : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Uppsala : Investigational Site Number 752001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Uppsala : Department of Oncology, University Hospital Uppsala

Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer

Uppsala : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Vaxjo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Basel : Universitätsspital Basel

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Genolier : IMO Clinique de Genolier

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Lausanne : Centre Hospitalier Universitaire Vaudois

Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer

Zurich : Urozentrum Zürich

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Kaohsiung : Investigational Site Number 158004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Taiching : Investigational Site Number 158002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Taichung : Investigational Site Number 158002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Taichung City :

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Tainan : Investigational Site Number 158003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Taipei : Investigational Site Number 158001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Taipei : Investigational Site Number 158001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tao-Yuan : Investigational Site Number 158003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Taoyuan County :

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Bangkok :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Ariana : Investigational Site Number 788001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sfax : Investigational Site Number 788004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sousse : Investigational Site Number 788003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Tunis : Investigational Site Number 788002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ankara : Investigational Site Number 792002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Antalya : Investigational Site Number 792003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bornova : Investigational Site Number 792001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Istanbul : Investigational Site Number 792002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Istanbul : Investigational Site Number 792001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kayseri : Investigational Site Number 792004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cherkasy : Investigational Site Number 804009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Dnipropetrovsk : Investigational Site Number 804004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Donetsk : Investigational Site Number 804010

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Ivano-Frankivsk : Investigational Site Number 804006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kharkov : Investigational Site Number 804003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kyiv : Investigational Site Number 804001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kyiv : Investigational Site Number 804002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lutsk : Investigational Site Number 804007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Uzhgorod : Investigational Site Number 804005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Zaporizhzhya : Investigational Site Number 804008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Addlestone : The Crouch Oak Family Practice Updated

GP Extended Action Triptorelin

Ashford : Dr Carter & Partners Updated

GP Extended Action Triptorelin

Aylesbury : Westongrove Research Centre, Aston Clinton Surgery Updated

GP Extended Action Triptorelin

Bath : St James' Surgery Updated

GP Extended Action Triptorelin

Bath : Clinical Research Unit, Oldfield Surgery Updated

GP Extended Action Triptorelin

Bath : Clinical Research Unit, The Pulteney Practice Updated

GP Extended Action Triptorelin

Bath : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Birmingham : Investigational Site Number 826002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Birmingham : Queen Elizabeth Hospital

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Birmingham : Queen Elizabeth Hospital

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Birmingham : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Blackpool : Waterloo Medical Centre Updated

GP Extended Action Triptorelin

Brighton : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bristol : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bury St. Edmunds : Woolpit Health Centre Updated

GP Extended Action Triptorelin

Cambridge : Addenbrookes Hospital Cambridge

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Cambridge : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Canterbury : Cossington House Surgery Updated

GP Extended Action Triptorelin

Cardiff : Velindre Cancer Centre

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Cardiff : Velindre Cancer Centre

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Chesterfield : Research Office, Avondale Surgery Updated

GP Extended Action Triptorelin

Chippenham : Clinical Research Dept., Rowden Surgery Updated

GP Extended Action Triptorelin

Chippenham : Clinical Research Unit, Hathaway Medical Centre Updated

GP Extended Action Triptorelin

Colchester : Investigational Site Number 826004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Corsham : The Porch Surgery Updated

GP Extended Action Triptorelin

East Horsley : The Medical Centre Updated

GP Extended Action Triptorelin

Glasgow : Investigational Site Number 826005

Prostate Cancer Clinical Trials

Alabama

Alaska

Arizona

Arkansas

California

Colorado

Connecticut

Delaware

District of Columbia

Florida

Georgia

Hawaii

Idaho

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maryland

Massachusetts

Michigan

Minnesota

Mississippi

Missouri

Montana

Nebraska

Nevada

New Jersey

New Mexico

New York

North Carolina

North Dakota

Ohio

Oregon

Pennsylvania

Rhode Island

South Carolina

South Dakota

Tennessee

Texas

Utah

Virginia

Washington

Wisconsin

Wyoming

Argentina

Australia

Austria

Belarus

Belgium

Bosnia and Herzegovina

Brazil

Bulgaria

Canada

Chile

China

Czech Republic

Denmark

Finland

France

Germany

Greece

Hungary

India

Ireland

Israel

Italy

Japan

Korea, Republic of

Latvia

Malaysia

Mexico

Netherlands

New Zealand

Norway

Peru

Poland

Portugal